1	Estimating the effects of exercise-based cardiac rehabilitation on health-related quality
2	of life in patients with myocardial infarction in Sweden: A registry-based study using
3	non-experimental methods
4	
5	Short title: Exercise-based cardiac rehabilitation and health-related quality of life
6	
7	Anja N. Stanke ¹ , Margrét Leósdóttir ^{1,2} , Maria Bäck ³ , Björn Ekman ^{1*}
8	¹ Department of Clinical Sciences, Malmö, Lund University, Sweden
9	² Department of Cardiology, Skane University Hospital, Malmö, Sweden
10	³ Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska
11	Academy, University of Gothenburg and Sahlgrenska University Hospital, Sweden
12	
13	BE ORCID id: 0000-0001-7630-7904.
14	ML ORCID id: 0000-0003-1677-1566.
15	MB ORCID id: 0000-0002-6031-7478.
16	
17	*Corresponding author: Björn Ekman, bjorn.ekman@med.lu.se
18	
19	ANS led the data analysis and the drafting of the manuscript. BE provided analytical support.
20	ML and MB provided support to the conceptualization of the study. All authors contributed to
21	the writing of the manuscript.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

23 Participation in exercise-based cardiac rehabilitation (EBCR) improves long-term prognosis 24 for patients following myocardial infarction (MI). Evaluating the effects of EBCR is 25 challenging due to the voluntary nature of participation in the program. Using register data on 26 18.978 patients hospitalized for MI in 2011 to 2013 in Sweden, a non-experimental study 27 design is employed to evaluate the effects of EBCR on the health-related quality of life 28 (HROoL). Conditional independence from non-random treatment assignment is considered 29 through set of potential-outcome (PO) models to estimate the average treatment effect (ATE) 30 and the ATE on the treated (ATET) of EBCR on HROoL using the EO-5D-3L instrument. 31 Changes in the EuroQoL Visual Analogue Scale (EQ-VAS; range 0 to 100) and the EQ5D-32 Index (range -0.594 to 1) between 6-10 weeks and one-year post-MI are compared between two groups of participants in EBCR (complete participants ≥ 3 months] and non-complete 33 34 participants [<3 months]) and non-participants (control group). In total, 43% of patients 35 participated in EBCR to some extent (12% complete, 31% non-complete). Participants showed greater improvement on the EQ-VAS scale compared with non-participants. Patients 36 37 who completed an EBCR program had a larger improvement (ATE of between 1.851-1.917 points; p < 0.001) compared with participants who did not complete the full program (0.974-38 39 1.017 points: p < 0.01). Full participation in the program increased the EO5D-Index of between 0.014 and 0.017 points (p < 0.05), while no statistically significant effect was 40 41 observed among non-completers. The effect of EBCR on HROoL was more pronounced 42 among younger patients and those reporting dyspnea and angina than older and non-43 symptomatic patients. Participating in EBCR may improve the health-related quality of life of 44 patients post-MI. The clinical relevance of the observed impact of EBCR on HRQoL warrants further investigation. The effects of EBCR participation can be readily estimated using 45 46 broadly applicable non-experimental approaches and commonly available register data.

47 **1 Introduction**

48 Individuals who suffer a myocardial infarction (MI) face an elevated risk of repeated events 49 and death [1] as well as significant impairments in health-related quality of life (HROoL) [2-50 4]. HRQoL is a multifaceted concept that assesses a person's overall functioning and well-51 being across physical, mental, and social dimensions of health [5]. Losses in HRQoL have 52 repeatedly been reported among patients with MI [2–4]. Furthermore, low HRQoL post-MI is 53 associated with an increased risk of repeated hospital admissions [6], major cardiovascular 54 events and death [7–9]. Consequently, secondary preventive measures aiming to prevent 55 recurrent cardiac events and promote HRQoL among survivors of MI are critical to the 56 effective management and care of this patient group. 57 Guidelines from the European Society of Cardiology for patients with acute coronary 58 syndromes [10] recommend the provision of cardiac rehabilitation (CR) in general, and 59 exercise-based CR (EBCR) in particular, due to its well-established positive effects on 60 cardiovascular risk factor management [11] and prognosis [12]. Although implementation of 61 EBCR programs varies across different settings, such programs generally involve medically 62 supervised physical exercise that combines aerobic and resistance training over a period of at 63 least three months. In Sweden, EBCR participation is routinely offered to post-MI patients 64 [13]. In particular, 24 EBCR sessions for 3 months, along with a pre-exercise and a post-65 exercise assessment, is recommended. 66 While extensive research demonstrates the positive effects of EBCR on objectively measured 67 risk factors, previous systematic reviews evaluating the impact of EBCR on HRQoL in 68 patients with coronary artery disease have reported inconsistent results [12, 14–16]. This may stem from differences across studies regarding study populations, length of follow-up, 69 70 HRQoL measurement tools, content, and dose of EBCR treatment. Although randomized

71 controlled trials (RCTs) are often considered the gold standard in the evaluation of treatment

72 effects [17], there are also methodological constraints to RCTs, including the potential for

rd selection-, performance-, and attrition bias [15, 16]. Moreover, the reliance on small samples

74 in RCTs raises concerns about external validity and generalizability.

75 Observational studies with representative samples can be beneficial in this context, in 76 particular when applying methods that go beyond mere establishment of an association [18, 77 19]. To date, only a few well-designed observational studies [20-22] have examined EBCR 78 participation and HROoL outcome measures. The findings of these studies suggest mixed 79 effects of EBCR on participants' quality of life. However, none of the studies have solely 80 assessed supervised exercise, but rather considered the impact of a combination of 81 components, including supervised exercise and other treatments, such as dietary and smoking 82 cessation counselling and stress management. Importantly, no study on this issue has applied 83 analytical methods that address the underlying assumption in treatment effect studies of 84 conditional independence between the outcome and treatment assignment. To address this gap 85 in the evidence base, we aimed to evaluate the effect of EBCR on self-reported HRQoL 86 among patients with MI using methods that allow identification of a treatment effect based on 87 observable factors that affect both treatment assignment and outcomes. Specifically, we 88 estimated the average treatment effects (ATE) of EBCR participation by fitting a set of 89 potential-outcome (PO) models to account for self-selection of patients into treatment status. 90 In addition, and building on previous research suggesting that exercise dosage may influence 91 the degree to which physical exercise improves HRQoL [23], we also aimed to investigate 92 whether a dose-response relationship exists between EBCR and HRQoL.

93 **2** Materials and methods

94 **2.1 Study design and sample**

95 We employed a retrospective cohort study design based on data from the Swedish Web-

96 system for Enhancement and Development of Evidence-based care in Heart disease Evaluated 97 According to Recommended Therapies (SWEDEHEART) [24]. The SWEDEHEART registry 98 collects data on a broad range of patient and treatment characteristics, including demographic 99 information, cardiovascular risk factor management, health behavior, recurrent cardiac events, 100 EBCR participation, and HRQoL. In 2013, 95% of all Swedish CR centers reported to 101 SWEDEHEART, covering 80% of all patients under the age of 75 who had been hospitalized 102 for MI and were alive one year after the acute event [25]. To track the entire patient pathway 103 from acute hospital care to outpatient rehabilitation, SWEDEHEART data is collected on 104 three occasions: at hospitalization (baseline) and at two follow-up visits: 6-10 weeks after MI 105 and 12-14 months after MI. The sample of patients with MI used in this study was drawn 106 from the registered MI cases in SWEDEHEART between 2011-2013 (made available for 107 research purposes on 15/01/2024). In total, 18,978 MI- patients were included, encompassing 108 all patients who had been diagnosed with MI within the three-year period, who attended both 109 follow-up visits, and had non-missing data on EBCR participation.

110 **2.2 Study variables and measures**

111 In SWEDEHEART, self-reported HRQoL is measured with the standardized EuroQol-Five-112 Dimensions-Three-Level Questionnaire (EQ-5D-3L) [26]. The EQ-5D-3L is validated for use 113 among patients with MI [27] and comprises two parts: a descriptive system (EQ5D-Index) 114 and a visual analog scale (EQ-VAS). The EQ5D-Index is a weighted summary score that 115 reflects an individual's health status across five dimensions (mobility, self-care, usual 116 activities, pain/discomfort, anxiety/depression) while taking into account the health norms of 117 the underlying population. The EQ5D-Index values are benchmarked against the norms of the 118 general population, which in the Swedish case is the UK population norm [28]. The score

119 ranges from negative values (representing a state considered worse than death) to 1

120 (representing full health).

121 The EQ-VAS captures an individual's perception of health status, with participants being 122 asked to rate their current health state on a scale ranging from 0 ("Worst health you can imagine") to 100 ("Best health you can imagine") [26]. To evaluate the impact of EBCR on 123 124 HRQoL, we assessed the change in EQ-VAS score (Δ EQ-VAS) and the change in EQ5D-125 Index score (Δ EO5D-Index) between the first and the second follow-up visits. 126 *Participation in EBCR* until the second follow-up visit served as the multivalued treatment 127 variable. Differentiating between no participation (non-participants), participation for less 128 than the recommended three months (non-completers), and participation for at least three

129 months (completers) allowed for the investigation of a potential dose-response relationship

130 between EBCR and HRQoL.

131 To model the relationship between EBCR and HRQoL, we utilized information on a range of

132 observable factors known to affect the quality of life of patients with MI from the

133 SWEDEHEART registry, including the age and sex of the patients, employment status,

134 smoking, diabetes, previous MI and/or stroke, dyspnea and/or angina symptoms, and physical

135 activity above average. In addition, an estimate of the distance from the patient's home to the

136 clinic was linked to the current dataset [11]. This measure was hypothesized to affect

137 participation in the EBCR program [29] but not to affect the outcome. As such, it serves as an

138 instrumental variable in the models enhancing the strength of the analysis.

139 To avoid underpowered categories, we dichotomized the categorical variables *employment*

140 status and smoking, differentiating between employed/non-employed, and smoker/non-

141 smoker. In SWEDEHEART, angina is rated based on the Canadian Cardiovascular Society

142 (CCS) grading of angina pectoris [30], while dyspnea is classified based on the New York

143 Heart Association (NYHA) Functional Classification system [31]. Angina and dyspnea were

144 considered present when patients reported symptoms rated as class II-IV on the CCS and

145 NYHA scales, respectively. The variables dyspnea and angina were dichotomized and

146 combined into the binary variable *dyspnea and/or angina symptoms* to capture a more

147 comprehensive measure of potential symptoms of a similar nature. The binary variables

148 *previous MI* and *previous stroke* were combined into the variable *previous MI and/or stroke*.

149 Finally, we created the variable *physical activity above average* to indicate whether a patient's

150 normal physical activity level (measured by the self-reported number of physical activity days

151 per week) was above or below the average observed in the sample.

The selection of the covariates was informed by insights from prior studies on the relationship between EBCR and HRQoL [7, 29, 32, 33]. Data on the covariates *dyspnea and/or angina symptoms* and *number of physical activity days per week* were collected during the first followup visit, while information on all other covariates was gathered at the time of MI. An overview of all variables used in the study is given in Table S1.

157 2.3 Statistical methods

158 To address the possibility of unobserved confounding, we employed potential outcomes 159 models to estimate the average treatment effects (ATE) and the average treatment effects on 160 the treated (ATET) [34]. Specifically, to obtain consistent estimates of the effects of EBCR on 161 HRQoL we used the following potential outcomes treatment effect estimators: regression 162 adjustment (RA), inverse probability weighting (IPW), inverse probability weighting with 163 regression adjustment (IPWRA), and augmented inverse probability weighting (AIPW) [35]. 164 To account for self-selection into treatment groups these approaches utilize observable 165 information to create comparability between the treatment group(s) and an untreated control 166 group [36]. While RA estimators model the outcome and IPW estimators the treatment 167 assignment process, the IPWRA and AIPW predictors embody a doubly-robust property by 168 predicting both the outcome and the treatment assignment process [35]. Doubly-robust

169 estimators come with the advantage that only one model needs to be correctly specified for

170 consistent estimation [35].

171 Our identification approach involved a series of steps, including: i) obtaining baseline 172 differences between the EBCR groups and the control group using independent samples t-173 tests and chi-square tests of independence, as appropriate; ii) comparing the observed mean 174 changes in EQ-VAS and EQ5D-Index between treatment groups by 1-year post-MI using 175 independent samples t-tests; iii) controlling for the effect of other variables that may distort the relationship between EBCR and HRQoL; iv) exploring whether the effect of EBCR on 176 177 HRQoL was strengthened or weakened depending on a patient's sex, age, dyspnea and/or 178 angina symptoms, and overall physical activity level by conducting interaction analyses; and 179 v) performing sensitivity checks to test the robustness of our findings. 180 In step iii, we addressed the potential for endogeneity bias by a) including age, sex, 181 employment status, dyspnea and/or angina symptoms, diabetes, smoking, and number of 182 physical activity days per week as potentially confounding factors in multiple linear 183 regression models (hereinafter referred to as "base models", see Table S2 and S3) and b) 184 employing the previously described potential outcomes treatment effect estimators: RA, IPW, 185 IPWRA, and AIPW. To model the outcome, we utilized the covariates age, sex, employment 186 status, dyspnea and/or angina symptoms, diabetes, smoking, and number of physical activity 187 days per week. The same covariates along with the variable distance to clinic were used to 188 predict treatment allocation. The variable smoking was only included in the EQ-VAS models, 189 as Wald test results indicated that including smoking in the EQ5D-Index models would 190 increase the error term without substantially improving the prediction. All data management 191 and analyses were done using Stata 17.

192 **2.4 Ethical considerations**

193 The study complied with the Declaration of Helsinki and was approved by The Regional

194 Ethical Review Board at Lund University, Sweden (Registration numbers 2014/6 and

195 2014/387). The need for informed participant consent was waived by the ethics review board

196 as all data were anonymized and the researchers did not have access to information that could

197 identify individual participants during or after the implementation of the study.

198 **3 Results**

199 **3.1 Descriptive statistics**

200 The total sample included almost 19,000 patients, around 12 percent of whom participated 201 fully in the EBCR program (completers) and 31 percent participated albeit <3 months (non-202 completers). Approximately one-third of the sample was female, and the sample's average 203 age was 63 years (s.d. 8.66 years), 42 percent were employed, and 29 percent were current 204 smokers at the time of hospitalization. With respect to comorbidities, around one-fifth of the 205 sample had suffered from previous MI and/or stroke, and 18 percent had diabetes at the time 206 of hospitalization. On average, patients reported being physically active on four days a week 207 at the time of the first follow-up visit. A detailed description of the study sample can be found 208 in Table 1.

Table 1. Descriptive statistics at baseline by participation status.

			Participation	Participation
	Total	No participation	< 3 months	\geq 3 months
	18,978	N = 10,761	N=5,841	N=2,376
Age, years				
Mean	62.78	63.22	61.83	63.17
SD	8.66	8.68	8.69	8.33
Male				
Ν	14,180	8,085	4,338	1,757
0⁄0	74.72	75.13	74.27	73.95
Employed at baseline				
N	7,598	3,994	2,650	954
0⁄0	42.31	39.27	47.76	42.63
Previous MI and/or stroke				
Ν	3,765	2,506	889	370
0⁄0	19.93	23.40	15.28	15.64
Dyspnea and/or angina symptoms at 1 st follow-up				
N	2,032	1,209	568	255
0⁄0	12.20	13.17	10.61	11.96
Diabetes at baseline				
Ν	3,413	2,171	871	371
0⁄0	18.02	20.21	14.96	15.65
Smoker at baseline				
Ν	5,405	3,390	1,510	505
0⁄0	29.10	32.16	26.42	21.79
Number of physical active days per week at 1 st follow-up				
Mean	4.05	3.73	4.45	4.47
SD	2.65	2.77	2.44	2.46
Distance to clinic, km				
Mean	22.04	23.23	20.25	20.98
SD	10.37	10.86	9.27	9.88

211 **3.2 Baseline differences between treatment groups**

212 Table 1 shows the baseline differences between the two groups of EBCR participants and the 213 control group for all covariates. While some differences between non-completers (EBCR <3 214 months) and completers (EBCR \geq 3 months) were evident, more notable differences were 215 observed between those attending EBCR and those not attending EBCR. Patients not 216 attending EBCR were more likely to be smokers, to be diagnosed with diabetes, to have 217 experienced previous MI and/or stroke, and to report dyspnea and/or angina symptoms 218 compared with patients attending EBCR. Also, non-participants were more often male, living 219 further away from the clinic, and reported a slightly more physically active lifestyle than participants. All observed intergroup differences, except for gender distribution, were 220 221 statistically significant (Table S4 and S5).

222 **3.2.1** Differences in HRQoL between and within treatment groups

223 The EQ5D-Index values of participants (completers and non-completers combined) and non-

224 participants at the first and second follow-up visits are presented in Figure 1.



Figure 1. EQ5D-Index scores with 95% Confidence Intervals at the 1st and 2nd follow-up visits by treatment group.

- 228 While among participants the EQ5D-Index score increased slightly between the follow-up
- visits (p=0.022), no such change in the EQ5D-Index score was observed for non-participants
- 230 (p=0.061). Employing independent samples t-tests, the observed difference between EBCR
- 231 participants and non-participants in Δ EQ5D-Index was statistically significant (p=0.003).
- 232 Intergroup differences for EQ-VAS are shown in Figure 2. Over the one-year follow-up
- period non-participants reported a mean increase of 1.5 points (p=0.0000) while EBCR
- 234 participants reported a mean increase of 2.9 points on the EQ-VAS scale (p =0.0000).



Figure 2. EQ-VAS scores with 95% Confidence Intervals at the 1st and 2nd follow-up visits by treatment group.

- 238 In addition to intergroup differences, we also found differences in HRQoL status within the
- EBCR treatment group. Specifically, we found that EBCR participants suffering from

- 240 dyspnea and/or angina symptoms had lower HRQoL scores at the first follow-up visit (EQ-
- 241 VAS: 61.6±18.3; EQ5D-Index: 0.73±0.24) compared to non-symptomatic EBCR participants

(EQ-VAS: 73.9 ±16.7; EQ5D-Index: 0.85±0.2) (p=0.0000). Similarly, HRQoL values at the
first follow-up visit were found to be lower among younger EBCR participants than among
older participants (Table S6).

245 **3.3 Potential-outcomes models**

Table 5 shows the estimated treatment effects of EBCR on Δ EQ-VAS from fitting the RA,

247 IPW, IPWRA, and AIPW models; ATE upper part and ATET lower part. Compared to non-

248 participation, participation in EBCR was associated with an increase in the absolute EQ-VAS

score by between 0.974 and 1.017 points among non-completers (EBCR < 3 months) and by

between 1.851 and 1.917 points among completers (EBCR \geq 3 months), after adjusting for

251 observable factors. The ATET of EBCR on EQ-VAS took on slightly smaller values and

ranged from 0.797 to 0.887 points among non-completers and from 1.733 to 1.857 points

among completers. All effect measures were statistically significant (Table 5) and aligned

with the findings of the base models (Tables S2 and S3), suggesting a significant albeit small

255 effect of EBCR on Δ EQ-VAS.

	RA	IPW	IPWRA	AIPW	
		ATE			
EBCR < 3 months	0.974**	0.994**	1.017**	1.014**	
	[0.331; 1.616]	[0.328; 1.660]	[0.350; 1.683]	[0.347; 1.680]	
$EBCR \ge 3$ months	1.917***	1.851***	1.852***	1.851***	
	[1.020; 2.815]	[0.921; 2.782]	[0.923; 2.781]	[0.922; 2.781]	
Ν	15,422	15,150	15,150	15,150	
		ATET			
EBCR < 3 months	0.887**	0.809*	0.797*	-	
	[0.257; 1.518]	[0.154; 1.464]	[0.142; 1.451]		
$EBCR \ge 3$ months	1.857***	1.743***	1.733***	-	
	[0.985; 2.729]	[0.850; 2.637]	[0.841; 2.626]		
N	15,422	15,150	15,150	-	

256	Table 5. Estimated	changes in EQ	D-VAS scores at one-	vear post-MI ((ATE and ATET).
	10010 01 2000000				

Notes: 95% confidence intervals in brackets (based on robust standard errors). * p < 0.05, ** p < 0.01, *** p < 0.001. Acronyms: RA stands for regression adjustment, IPW stands for inverse probability weights, IPWRA stands for inverse-probability-weighted regression adjustment, AIPW stands for augmented inverse-probability weights.

257 The corresponding results for the EQ5D-Index measure of HRQoL are presented in Table 6.

258 For those who participated less than the recommended three months in the EBCR program no

259 effect was found compared with those who did not participate at all. In contrast, those who

260 completed the full program did experience a statistically significant effect of the program

261 compared with those who did not participate. Compared to the ATE values, the ATET values

- were statistically significant for both treatment groups, amounting to 0.013 points among
- 263 completers and ranging from 0.009 to 0.010 points among non-completers.

	RA	IPW	IPWRA	AIPW
		ATE		
EBCR < 3 months	0.008	0.008	0.008	0.008
	[-0.000; 0.016]	[-0.001; 0.016]	[-0.000; 0.016]	[-0.000; 0.016]
		**	0 04 -* *	0 04 - **
EBCR \geq 3 months	0.014*	0.017**	0.017**	0.017**
	[0.002; 0.025]	[0.005; 0.029]	[0.005; 0.029]	[0.005; 0.029]
N	15,737	15,458	15,458	15,458
		ATET		
EBCR < 3 months	0.009*	0.010*	0.010*	-
	[0.002; 0.017]	[0.002; 0.018]	[0.002; 0.018]	
$EBCR \ge 3$ months	0.013*	0.013*	0.013*	-
	[0.002; 0.024]	[0.002; 0.024]	[0.002; 0.024]	
N	15,737	15,458	15,458	-

264 Table 6. Estimated changes in EQ5D-Index at one-year post-MI (ATE and ATET).

Notes: 95% confidence intervals in brackets (based on robust standard errors). * p < 0.05, ** p < 0.01, *** p < 0.001. See Table 5 for model acronyms.

To assess the validity of our treatment effect estimations, we tested whether there was an overlap in the covariate distributions between the control group and the treatment groups. Treatment group overlap is a key assumption underlying potential outcome models [34] and was found to be satisfied in the present study (Figures S1 and S2).

269 **3.3.1 Heterogenous and marginal effects**

270 Assuming that the effect of EBCR on HRQoL may not solely depend on the amount of time

271 individuals spend on EBCR participation but also on other patient characteristics, we

conducted interaction analyses using the base models described earlier (Table S2-S3). The

273 results suggest that the effect of EBCR on Δ EQ-VAS did not depend on sex, age, and self-

- 274 reported physical activity while being dependent on the presence of dyspnea and/or angina
- symptoms (Table S7). Specifically, while all measures were statistically significant, the
- estimated average change in EQ-VAS score appeared to be notably bigger in EBCR
- 277 participants with dyspnea and/or angina symptoms (estimated change: 6.20 7.32 points) than

- 278 in EBCR participants without these symptoms (estimated change: 2.02 - 2.94 points; Figure
- 279 3).



280

Figure 3. Marginal effects of EBCR on AEQ-VAS by symptoms of dyspnea and/or 281 282

angina.

283 Notes: Angina was considered present when symptoms were rated as class II-IV on the Canadian

284 Cardiovascular Society (CCS) grading of angina pectoris. Dyspnea was considered present when

285 symptoms were rated as class II-IV on the New York Heart (NYHA) Association Functional 286 Classification system.

287 The effect of EBCR on Δ EQ5D-Index was found to be independent of dyspnea and/or angina

288 symptoms as well as patients' self-reported physical activity levels (Table S8). In contrast, the

289 improvement in EQ5D-Index over the one-year period appeared to decline with increasing

290 age, eventually losing statistical significance among patients aged 65 years and older (Figure

291 4).



292

293 Figure 4. Marginal effects of EBCR on ΔEQ5D-Index by age.

294

3.4 Sensitivity analyses 295

296 Adjusting the estimated standard errors for clustering by grouping patients treated within the same clinic into the same cluster, altered some of the reported findings. While the results of 297 the potential outcomes models suggested an effect of EBCR \geq 3 months on Δ EQ5D-Index 298 299 (Table 6), neither EBCR \leq 3 months nor EBCR \geq 3 months were significantly associated with 300 Δ EO5D-Index after employing clustered standard errors (Table S9-S10). In contrast, the 301 findings on Δ EQ-VAS remained unaffected by clustering (not shown). Excluding patients 302 over 74 years of age from the analyses did not alter the reported findings in any material way 303 (not shown). To investigate the robustness of our findings we also refitted the models while 304 removing Δ EQ-VAS values over ±90 and Δ EQ5D-Index values over ±0.9. This did not 305 change the results in any significant way (not shown).

Discussion 4 306

307 In this study we examined the effect of EBCR on HROoL using nationwide registry data on 308 Swedish patients with MI. For this purpose, we gradually employed more evolved regression 309 modelling techniques to address the non-randomized selection into treatment groups. In doing 310 so, this study demonstrates the ability to evaluate the effects of EBCR participation on 311 relevant outcomes in a non-experimental setting by applying a non-experimental approach. 312 The results of our treatment effect analyses suggest a positive effect of EBCR on the HRQoL 313 of patients with MI. Specifically, we found that EBCR participants experience a statistically 314 significantly greater improvement in EQ-VAS within one-year post-MI than their non-315 participating counterparts. In finding an effect of EBCR on EQ-VAS, our findings are in line 316 with a recent RCT by Campo et al. [37]. The authors of this study assessed the effect of a 317 combined center-based and home-based exercise program among elderly patients with acute 318 coronary syndrome in Italy and found a statistically significant effect on EQ-VAS, in favor of 319 EBCR participants. In contrast, no effect of EBCR on EO-VAS was observed in two earlier 320 Swedish RCTs [38, 39], which assessed the effect of supervised exercise on a small group of 321 elderly patients hospitalized for acute coronary events. Using almost the same sample the 322 authors found no significant effect of EBCR on EQ-VAS, neither at one-year [38] nor at 3-6 323 vears follow-up [39]. The contradictory results may arise from differences in sample 324 selection, study design and statistical methods between the reported studies. For example, 325 while our study benefitted from the high coverage of the SWEDEHEART registry, the two 326 earlier Swedish RCTs included mainly elderly male patients, who were hospitalized for MI 327 but also for other coronary events, diminishing the comparability to our findings. 328 Regarding EQ5D-Index, we found that EBCR completers experienced a greater increase in 329 their EQ5D-Index score over the one-year follow-up period than their non-participating 330 counterparts. In contrast, no such effect was observed for non-completers, suggesting that the 331 effect of EBCR on HRQoL may be dose dependent. However, after adjusting the estimated

332 standard errors for clustering at the clinic level, the effect previously observed for EBCR 333 completion was no longer statistically significant. This points to the possibility that variations 334 in EBCR treatment across clinics may partly explain the relationship between EBCR and 335 HRQoL. Indeed, variations in the availability, quality, content, and duration of EBCR 336 programs in Sweden have been previously reported [40]. Therefore, the possibility of a cluster 337 effect due to intraclass correlations among patients treated within the same hospital appears 338 feasible. However, despite finding no overall effect of EBCR on EQ5D-Index after 339 accounting for differences between CR clinics, there may still be an effect of EBCR on 340 EQ5D-Index within certain subgroups. Specifically, our heterogeneous effect analyses 341 revealed statistically significant marginal effects for EQ5D-Index among younger EBCR 342 participants. This finding suggests that younger patients may derive greater HRQoL-related 343 benefits from engaging in EBCR than older patients. 344 Inconsistent results regarding the effect of EBCR on EO5D-Index have also been reported in 345 earlier studies. Namely, while the previously described Swedish RCTs [38, 39] found no 346 effect on EQ5D-Index at one-year [38] or 3-6 years after the coronary event [39], the RCT by 347 Campo et al. [37], found significantly greater improvements in all EQ-5D dimensions except 348 for self-care among program attendees. However, Campo et al. did not report an overall

349 EQ5D-Index score and exclusively enrolled older patients with acute coronary syndrome and

350 restricted physical capabilities, limiting the comparability to our study.

351 In finding an overall effect for EQ-VAS but not for EQ5D-Index, this study aligns with

352 previous systematic reviews [14, 15] reporting contradictory findings on the effect of EBCR

353 on HRQoL, depending on the HRQoL measurement tool used and the HRQoL dimensions

354 explored. For instance, an RCT using visual analogue scales other than EQ-VAS to assess the

355 effect of EBCR on HRQoL in a sample of predominantly male patients with MI found

356 significantly greater improvements in HRQoL among EBCR participants compared to non-

357 participants [41]. Based on the findings of the present study, it therefore cannot be ruled out

that the estimated treatment effect of EBCR might have differed if HRQoL measurement

tools other than the EQ-5D-3L questionnaire had been used.

The current study suggests a dose-response relationship between EBCR and HRQoL with completers deriving greater benefits from EBCR than non-completers. This aligns with prior research reporting better HRQoL outcomes with increasing levels of activity [23]. Besides treatment dosage, disease severity and patient age seem to play a role in determining the extent to which EBCR impacts HRQoL. Specifically, the results of our heterogenous effect analyses suggest that EBCR participants with dyspnea and/or angina symptoms experience larger improvements in EQ-VAS than participants without these symptoms.

367 The more pronounced limitation in HRQoL reported at the first follow-up by participants with 368 dyspnea and/or angina symptoms as well as younger participants may be one reason for their 369 higher responsiveness to the EBCR program. On the other hand, the observed variations in 370 effect size between participant subgroups may also result from the EQ-5D-3L questionnaire 371 becoming less sensitive in detecting actual changes in HRQoL as HRQoL values increase 372 [42]. This phenomenon, referred to as "ceiling effect" [43], appears feasible in the current 373 context, given that participants with dyspnea and/or angina symptoms as well as participants 374 of younger age reported lower HRQoL values at the first follow-up visit compared to their 375 symptom-free and older counterparts. In finding no statistically significant marginal effects of 376 EBCR on EQ5D-Index among older participants, our study aligns with previous research by 377 Ståhle et al. [44] and Sandström et al. [38], who found no effect of EBCR on EQ5D-Index 378 among elderly MI patients in Sweden. In contrast Campo et al. [37] reported a significant 379 effect of EBCR on all EQ5D dimensions (except for self-care) in 70+-year-old patients with 380 acute coronary syndrome and limited physical performance. However, considering that their 381 patients had notably lower baseline HRQoL levels compared to the elderly patients in our

382 study, their patients might have been more receptive to the positive effects of EBCR, and 383 ceiling effects may have been less of a concern, possibly explaining the conflicting findings. 384 Overall, we found a statistically significant yet small effect of EBCR participation on the 385 change in EQ-VAS during follow-up. Whether this effect is clinically meaningful is difficult 386 to answer given that there is no established minimum clinically important difference (MCID) 387 for EQ-VAS in patients with MI. However, given that previous studies on patients with 388 chronic diseases other than cardiovascular conditions have reported larger MCIDs for EO-389 VAS, ranging from 6.9 to 10.8 points [45–47], the clinical meaningfulness is to be 390 questioned. In contrast, the effect of EBCR found among participants with dyspnea and/or 391 angina symptoms (marginal means ranging from 6.2 to 7.32 points for EQ-VAS, Figure 3) 392 approached the above mentioned MCIDS, potentially indicating clinical meaningfulness in 393 this patient subgroup. The statistically significant marginal effects of EBCR on EQ5D-Index 394 scores observed among participants aged 60 and younger were also found to be small, again 395 raising concerns about their clinical meaningfulness.

396 The current study sought to address the challenges arising from the non-randomized 397 allocation of EBCR treatment by utilizing potential outcomes models. Although these models 398 allowed for a more precise treatment effect estimation by controlling for observable factors, 399 the causal connection between EBCR and HROoL remains unclear, as potential distortions 400 from self-selection bias cannot be completely ruled out. For instance, previous studies found 401 that indicators of socioeconomic status are associated with both EBCR attendance [48] and 402 HRQoL [49]. In the current study, we did not have access to data on socioeconomic status, 403 introducing the possibility of unobserved confounding. Therefore, more advanced statistical 404 techniques accounting for the possibility of unobserved confounding, such as instrumental 405 variable techniques, should be considered for future research.

406 A limitation of the SWEDEHEART dataset is that information on the covariates *number of*

407 physically active days per week, and dyspnea and/or angina symptoms, as well as on EQ-VAS

- 408 and EQ5D-Index is only collected at the 1st follow-up and 2nd follow-up visit, while no
- 409 measurements for these variables are performed during hospitalization. Moreover, at the time
- 410 of the study information on when patients actually started their EBCR program was not
- 411 collected in SWEDEHEART [13]. In benefiting from the high coverage of SWEDEHEART,
- 412 this study more closely reflected the actual MI population than previous highly selective
- 413 RCTs. Nevertheless, it should be noted that our findings may not be generalizable to patients
- 414 over 74 years of age, due to the age limit for mandatory registration of patients in
- 415 SWEDEHEART being set at 74 years during the study period [50].

416 **5** Conclusions

417 Participation in EBCR after suffering from an MI may improve patients' HRQoL, especially 418 in younger patients and those with symptoms of dyspnea and/or angina. By applying rigorous 419 quasi-experimental methods to readily available register data, this study added to the existing 420 evidence of the effect of EBCR on patients' HROoL after MI, while aiming to address the 421 methodological challenges arising from self-selection into EBCR. Given the observed 422 variability in the effect of EBCR on HRQoL across patient subgroups, further research into 423 the impact of EBCR after MI is warranted. To further advance our understanding of this topic, 424 future studies should address the methodological shortcomings of previous research, such as 425 limited generalizability and selection bias. Importantly, our study demonstrates the ability to 426 evaluate the effects of a program such as EBCR to which patients self-select using broadly 427 available register data.

428 6 References

429	1.	Johansson S.	Rosengren A,	Young K,	Jennings E.	. Mortality	y and morbidity	y trends after th
-					/ /			

430 first year in survivors of acute myocardial infarction: a systematic review. BMC

431 Cardiovasc Disord. 2017;17:53. doi:10.1186/s12872-017-0482-9.

- 432 2. Dodson JA, Arnold SV, Reid KJ, Gill TM, Rich MW, Masoudi FA, et al. Physical
- 433 function and independence 1 year after myocardial infarction: observations from the
- 434 Translational Research Investigating Underlying disparities in recovery from acute
- 435 Myocardial infarction: Patients' Health status registry. Am Heart J. 2012;163:790–6.

436 doi:10.1016/j.ahj.2012.02.024.

- 437 3. Mollon L, Bhattacharjee S. Health related quality of life among myocardial infarction
- 438 survivors in the United States: a propensity score matched analysis. Health Qual Life

439 Outcomes. 2017;15:235. doi:10.1186/s12955-017-0809-3.

- 440 4. Schweikert B, Hunger M, Meisinger C, König H-H, Gapp O, Holle R. Quality of life
- 441 several years after myocardial infarction: comparing the MONICA/KORA registry to the

442 general population. Eur Heart J. 2009;30:436–43. doi:10.1093/eurheartj/ehn509.

- 443 5. Hays RD, Reeve BB. Measurement and Modeling of Health-Related Quality of Life. In:
- 444 Killewo J, Heggenhougen HK, Quah SR, editor. Epidemiology and Demography in

445 Public Health. San Diego: Academic Press; 2010. 195–205.

- 446 6. Myers V, Gerber Y, Benyamini Y, Goldbourt U, Drory Y. Post-myocardial infarction
- 447 depression: increased hospital admissions and reduced adoption of secondary prevention
- 448 measures--a longitudinal study. J Psychosom Res. 2012;72:5–10.
- 449 doi:10.1016/j.jpsychores.2011.09.009.
- 450 7. Pocock S, Brieger DB, Owen R, Chen J, Cohen MG, Goodman S, et al. Health-related
- 451 quality of life 1-3 years post-myocardial infarction: its impact on prognosis. Open Heart
- 452 2021; 8:e001499. doi:10.1136/openhrt-2020-001499.

- 453 8. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted
- 454 prognostic association of depression following myocardial infarction with mortality and
- 455 cardiovascular events: individual patient data meta-analysis. Br J Psychiatry.
- 456 2013;203:90–102. doi:10.1192/bjp.bp.112.111195.
- 457 9. Soloveva A, Gale CP, Naung Tun H, Hurdus B, Aktaa S, Palin V, et al. Associations of
- 458 health-related quality of life with major adverse cardiovascular and cerebrovascular
- 459 events for individuals with ischaemic heart disease: systematic review, meta-analysis and
- 460 evidence mapping. Open Heart 2023; 10:e002452. doi:10.1136/openhrt-2023-002452.
- 461 10. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021
- 462 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J.
- 463 2021;42:3227–337. doi:10.1093/eurheartj/ehab484.
- 464 11. Michelsen HÖ, Henriksson P, Wallert J, Bäck M, Sjölin I, Schlyter M, et al.
- 465 Organizational and patient-level predictors for attaining key risk factor targets in cardiac
- 466 rehabilitation after myocardial infarction: The Perfect-CR study. Int J Cardiol.
- 467 2023;371:40–8. doi:10.1016/j.ijcard.2022.09.012.
- 468 12. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler A-D, Taylor RS.
- 469 Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst
- 470 Rev. 2021;11:CD001800. doi:10.1002/14651858.CD001800.pub4.
- 471 13. Wittboldt S, Leosdottir M, Ravn Fischer A, Ekman B, Bäck M. Exercise-based cardiac
- 472 rehabilitation after acute myocardial infarction in Sweden standards, costs, and
- 473 adherence to European guidelines (The Perfect-CR study). Physiother Theory Pract.
- 474 2024;40:366–76. doi:10.1080/09593985.2022.2114052.
- 475 14. Candelaria D, Randall S, Ladak L, Gallagher R. Health-related quality of life and
- 476 exercise-based cardiac rehabilitation in contemporary acute coronary syndrome patients: a
- 477 systematic review and meta-analysis. Qual Life Res. 2020;29:579–92.
- 478 doi:10.1007/s11136-019-02338-y.

- 479 15. Mansilla-Chacón M, Gómez-Urquiza JL, Martos-Cabrera MB, Albendín-García L,
- 480 Romero-Béjar JL, La Cañadas-De Fuente GA, Suleiman-Martos N. Effects of Supervised
- 481 Cardiac Rehabilitation Programmes on Quality of Life among Myocardial Infarction
- 482 Patients: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis. 2021;8:166.
- 483 doi:10.3390/jcdd8120166.
- 484 16. Francis T, Kabboul N, Rac V, Mitsakakis N, Pechlivanoglou P, Bielecki J, et al. The
- 485 Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With
- 486 Coronary Artery Disease: A Meta-analysis. Can J Cardiol. 2019;35:352–64.
- 487 doi:10.1016/j.cjca.2018.11.013.
- 488 17. Gertler PJ, Martinez S, Premand P, Rawlings LB, Vermeersch CMJ. Impact Evaluation in

489 Practice. 2nd ed. Washington DC: World Bank; 2016.

- 490 18. Glass TA, Goodman SN, Hernán MA, Samet JM. Causal inference in public health. Annu
 491 Rev Public Health. 2013;34:61–75. doi:10.1146/annurev-publhealth-031811-124606.
- 492 19. Hernán MA. The C-Word: Scientific Euphemisms Do Not Improve Causal Inference

493 From Observational Data. Am J Public Health. 20;108:616–9.

- 494 doi:10.2105/AJPH.2018.304337.
- 495 20. Hurdus B, Munyombwe T, Dondo TB, Aktaa S, Oliver G, Hall M, et al. Association of
- 496 cardiac rehabilitation and health-related quality of life following acute myocardial

497 infarction. Heart. 2020;106:1726–31. doi:10.1136/heartjnl-2020-316920.

498 21. Kureshi F, Kennedy KF, Jones PG, Thomas RJ, Arnold SV, Sharma P, et al. Association

- 499 Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute
- 500 Myocardial Infarction. JAMA Cardiol. 2016;1:980–8. doi:10.1001/jamacardio.2016.3458.
- 501 22. Sinnadurai S, Sowa P, Jankowski P, Gąsior Z, Kosior DA, Haberka M, et al. Effects of
- 502 cardiac rehabilitation on risk factor management and quality of life in patients with
- 503 ischemic heart disease: a multicenter cross-sectional study. Pol Arch Intern Med.
- 504 2021;131:617–25. doi:10.20452/pamw.16019.

- 505 23. Huber A, Höfer S, Saner H, Oldridge N. A little is better than none: the biggest gain of
- 506 physical activity in patients with ischemic heart disease. Wien Klin Wochenschr.
- 507 2020;132:726–35. doi:10.1007/s00508-020-01767-x.
- 508 24. Jernberg T, Held C, Johanson P, Hambraeus K, Cider Å, Svennberg L, et al.
- 509 SWEDEHEART: Annual report 2012. Stockholm: Karolinska University Hospital; 2013.
- 510 25. Hambraeus K, Leósdóttir M, Nilsson L. SEPHIA Secondary prevention following
- 511 coronary intensive care. In: SWEDEHEART: Annual report 2013. Stockholm; 2014.
- 512 p. 42–57.
- 513 26. EuroQol Research Foundation. EQ-5D-3L User Guide [Internet]. Rotterdam: EuroQol
- 514 Research Foundation; 2018 [Cited 2024 Dec 12]. Available
- 515 from: https://euroqol.org/publications/user-guides/.
- 516 27. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-5D quality of life
- 517 instrument in patients after myocardial infarction. Qual Life Res. 2005;14:95–105.
- 518 doi:10.1007/s11136-004-0614-4.
- 519 28. Janssen B, Szende A. Population Norms for the EQ-5D. In: Szende A, Janssen B, Cabases
- 520 J, editors. Self-Reported Population Health: An International Perspective based on EQ-
- 521 5D. Dordrecht (NL): Springer; 2014. p. 19–30.
- 522 29. Borg S, Öberg B, Leosdottir M, Lindolm D, Nilsson L, Bäck M. Factors associated with
- 523 non-attendance at exercise-based cardiac rehabilitation. BMC Sports Sci Med Rehabil.
- 524 2019;11:13. doi:10.1186/s13102-019-0125-9.
- 525 30. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54:522–3.
- 526 doi:10.1161/circ.54.3.947585.
- 527 31. American Heart Association. Classes and Stages of Heart Failure [Internet]. Dallas:
- 528 American Heart Association; [last reviewed 2023 Jun 7; Cited 2024 Dec 12]. Available
- 529 from: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-
- 530 of-heart-failure.

- 531 32. Bäck M, Öberg B, Krevers B. Important aspects in relation to patients' attendance at
- 532 exercise-based cardiac rehabilitation facilitators, barriers and physiotherapist's role: a
- 533 qualitative study. BMC Cardiovasc Disord. 2017;17:77. doi:10.1186/s12872-017-0512-7.
- 33. Kang K, Gholizadeh L, Inglis SC, Han H-R. Correlates of health-related quality of life in
- 535 patients with myocardial infarction: A literature review. Int J Nurs Stud. 2017;73:1–16.
- 536 doi:10.1016/j.ijnurstu.2017.04.010.
- 537 34. Wooldridge JM. Econometric Analysis of Cross Section and Panel Data. 2nd ed.
- 538 Cambridge: The MIT Press; 2010.
- 539 35. StataCorp. STATA Treatment-Effects Reference Manual: Potential
- 540 Outcomes/Counterfactual outcomes: Release 17. College Station Texas: StataCorp LLC;
- 541 2021.
- 542 36. Rubin DB. Causal Inference Using Potential Outcomes. Journal of the American
- 543 Statistical Association. 2005;100:322–31. doi:10.1198/016214504000001880.
- 544 37. Campo G, Tonet E, Chiaranda G, Sella G, Maietti E, Bugani G, et al. Exercise

545 intervention improves quality of life in older adults after myocardial infarction:

- 546 randomised clinical trial. Heart. 2020;106:1658–64. doi:10.1136/ heartjnl-2019-316349.
- 547 38. Sandström L, Ståhle A. Rehabilitation of elderly with coronary heart disease –
- 548 Improvement in quality of life at a low cost. Advances in Physiotherapy. 2005;7:60–6.
- 549 doi:10.1080/14038190510010287.
- 550 39. Hage C, Mattsson E, Ståhle A. Long-term effects of exercise training on physical activity
- 551 level and quality of life in elderly coronary patients--a three- to six-year follow-up.
- 552 Physiother Res Int. 2003;8:13–22. doi:10.1002/pri.268.
- 40. Ögmundsdottir Michelsen H, Sjölin I, Schlyter M, Hagström E, Kiessling A, Henriksson
- P, et al. Cardiac rehabilitation after acute myocardial infarction in Sweden evaluation of
- 555 programme characteristics and adherence to European guidelines: The Perfect Cardiac

556 Rehabilitation (Perfect-CR) study. Eur J Prev Cardiol. 2020;27:18–27.

557 doi:10.1177/2047487319865729.

- 41. Dugmore LD, Tipson RJ, Phillips MH, Flint EJ, Stentiford NH, Bone MF, Littler WA.
- 559 Changes in cardiorespiratory fitness, psychological wellbeing, quality of life, and
- 560 vocational status following a 12 month cardiac exercise rehabilitation programme. Heart.
- 561 1999;81:359–66. doi:10.1136/hrt.81.4.359.
- 562 42. Christiansen ASJ, Møller MLS, Kronborg C, Haugan KJ, Køber L, Højberg S, et al.
- 563 Comparison of the three-level and the five-level versions of the EQ-5D. Eur J Health
 564 Econ. 2021;22:621–8. doi:10.1007/s10198-021-01279-z.
- 565 43. Garin O. Ceiling Effect. In: Michalos AC, editor. Encyclopedia of Quality of Life and
- 566 Well-Being Research. Dordrecht: Springer; 2014. p. 631–633. doi:10.1007/978-94-007567 0753-5_296.
- 568 44. Ståhle A, Mattsson E, Rydén L, Unden A, Nordlander R. Improved physical fitness and
 569 quality of life following training of elderly patients after acute coronary events. A 1 year

570 follow-up randomized controlled study. Eur Heart J. 1999;20:1475–84.

- 571 doi:10.1053/euhj.1999.1581.
- 572 45. Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SSC, Man WD-C. The EQ-

573 5D-5L health status questionnaire in COPD: validity, responsiveness and minimum

574 important difference. Thorax. 2016;71:493–500. doi:10.1136/thoraxjnl-2015-207782.

575 46. Chen P, Lin K-C, Liing R-J, Wu C-Y, Chen C-L, Chang K-C. Validity, responsiveness,

- and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing
- 577 rehabilitation. Qual Life Res. 2016;25:1585–96. doi:10.1007/s11136-015-1196-z.
- 578 47. Del Corral T, Fabero-Garrido R, Plaza-Manzano G, Navarro-Santana MJ, Fernández-de-

579 Las-Peñas C, López-de-Uralde-Villanueva I. Minimal Clinically Important Differences in

580 EQ-5D-5L Index and VAS after a Respiratory Muscle Training Program in Individuals

- 581 Experiencing Long-Term Post-COVID-19 Symptoms. Biomedicines. 2023;11:2522.
- 582 doi:10.3390/biomedicines11092522.
- 583 48. Ohm J, Skoglund PH, Häbel H, Sundström J, Hambraeus K, Jernberg T, Svensson P.
- 584 Association of Socioeconomic Status With Risk Factor Target Achievements and Use of
- 585 Secondary Prevention After Myocardial Infarction. JAMA Netw Open. 2021;4:e211129.
- 586 doi:10.1001/jamanetworkopen.2021.1129.
- 587 49. Skodova Z, Nagyova I, van Dijk JP, Sudzinova A, Vargova H, Rosenberger J, et al.
- 588 Socioeconomic inequalities in quality of life and psychological outcomes among cardiac

589 patients. Int J Public Health. 2009;54:233–40. doi:10.1007/s00038-009-7086-9.

- 590 50. Hambraeus K, Leósdóttir M, Nilsson L. SEPHIA Secondary prevention following
- 591 coronary intensive care. In: Jernberg T, editor. SWEDEHEART: Annual report 2013.
- 592 Stockholm; 2014. p. 42–57.